AgeX Therapeutics Inc (AGE)

[saxonia40271]

The last 8-K states that they‘ve now drawn $10.16 million, including the recent draw. $3 million remain, unless it‘s rolled over or augmented again.

I don’t expect AgeX to become a fully-owned subsidiary of Juvenescence, or rather JuvRegeneration. That would eliminate the public listing, from they stand to benefit greatly, once the tide turns. The other owners also wouldn’t part company with their shares.

The more interesting question is what’s to become of Reverse Bio, the AgeX subsidiary, which is far more interesting than AgeX itself. At this stage, we can safely say that it’s too soon to take it public. They’re currently in the process of raising funds for a POC study of iTR in animals, in preparation for an IND application.